PDF(Pubmed)
Abstract：
Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of these therapies. This study used inverse probability of treatment weighting to indirectly compare treatment outcomes of epcoritamab from the EPCORE NHL-1 trial with individual patient data from clinical practice cohorts treated with chemoimmunotherapy (CIT) and novel therapies (polatuzumab-based regimens, tafasitamab-based regimens, and chimeric antigen receptor T-cell [CAR T] therapies) for third-line or later R/R large B-cell lymphoma (LBCL) and DLBCL. In this analysis, epcoritamab demonstrated significantly better response rates and overall survival rates than CIT, polatuzumab-based regimens, and tafasitamab-based regimens. No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL.
摘要：
在≥2行治疗后，许多疗法可用于治疗复发性/难治性（R/R）弥漫性大B细胞淋巴瘤（DLBCL），尽管关于这些疗法的相对有效性的证据很少。本研究使用治疗权重的逆概率来间接比较EPCORENHL-1试验中的epcoritamab的治疗结果与接受化学免疫疗法（CIT）和新疗法（基于polatuzumab的方案，以塔法他单抗为基础的方案，和嵌合抗原受体T细胞[CART]疗法）用于三线或更高的R/R大B细胞淋巴瘤（LBCL）和DLBCL。在这个分析中,epcoritamab表现出明显优于CIT的缓解率和总体生存率，基于polatuzumab的方案，和以塔法他单抗为基础的方案。在R/RLBCL中，与CART相比，epcoritamab的反应率或生存率没有统计学上的显着差异。
